How should we look to history to make sense of Luigi Mangione’s alleged murder of UnitedHealthcare CEO Brian Thompson?
Luigi Mangione has been arrested for murdering UnitedHealthcare CEO Brian Thompson, prompting discussions on historical parallels between today’s societal issues and the Gilded Age, emphasizing significant differences and challenges within both eras.
I’m a Gilded Age historian who has drawn parallels between our current moment and the late 19th century, two periods known for staggering economic inequality and sweeping technological change.
As many journalists and pundits would have it, both Thompson and Mangione appear to have wandered into the New York borough of Manhattan from the late 19th century.
In their interpretation, the two Gilded Ages are no longer running on parallel tracks. They have collided, mixing their occupants and baggage into a chaotic mess.
New York Times columnist Bret Stephens casts Thompson as a character out of a Horatio Alger novel: a working-class hero who pulled himself up by the bootstraps. Also writing in The New York Times, sociologist Zeynip Tufekci comes close to making Luigi Mangione a reincarnation of Alexander Berkman, the anarchist who tried to assassinate industrialist Henry Clay Frick. Over in The New Yorker, Dhruv Khullar suggests that in its arbitrariness and callousness, the prototype for the U.S. medical system, which Mangione excoriated in his manifesto, originated somewhere in the Gilded Age.
Today’s historians and journalists obviously think the past has much to teach their fellow citizens. And their motives are sensible: They want to push back against the idea that the past is irrelevant, that everything important has occurred in the past 15 minutes – a view reflected in a favorite phrase of President-elect Donald Trump to describe whatever crisis du jour is afflicting the United States: “We’ve never seen anything like it.”
Advertisement
So comparisons between two periods can serve as a brake on hasty claims that everything has changed and that the current moment is unprecedented. But in my view, specific comparisons often make a categorical mistake. They substitute modern beliefs and judgments for those of people in the past.
In the immediate aftermath of the murder, Tufekci wrote that “The currents we are seeing are expressions of something more fundamental. We’ve been here before. And it wasn’t pretty.”
Wait, slow down: “We” have not been here before. The major, most obvious – and virtually always ignored – difference between the Gilded Age and our own time is that we did not live in it. None of us were alive in the late 19th century. The people who were alive back then didn’t think like us or act like us. Finding structural similarities does not turn writers into Nostradamus, able to discern the signs and predict the future.
It is all too easy to use the past as a tool for driving home lessons derived from modern beliefs or ideologies. Without knowing much about either Thompson or Mangione – let alone anarchists or Horatio Alger heroes – Mangione becomes the equivalent of a 19th-century avenger of the working class, while Thompson is a modern “Ragged Dick,” rising to his post through pluck and hard work.
Most popular and political appeals to history are not just superficial, they are also quite ahistorical. Nowhere is this more apparent than in the courts.
Jonathan Gienapp’s new and brilliant book, “Against Constitutional Originalism,” eviscerates what he describes as the sloppiness, ahistoricism and anachronisms of the U.S. Supreme Court’s conservative members, who often justify their decisions by invoking what the nation’s founders intended. According to Gienapp, their core sin is simple: They are ventriloquists putting their modern ideas in the founders’ mouths and claiming they have recovered original meanings.
Emerging from the morass
This ahistorical thinking runs across the political spectrum. It comes from asking the wrong questions, and thinking that structural similarities produce roughly identical outcomes.
Advertisement
The two periods share more than soaring inequality and vast technological change. There were attacks on racism and resurgent racism; mass immigration and backlash against it; frequent swings in party control; economic booms and busts; a dearth of bold leadership; failures in governance; and outbursts of violence.
Both eras also experienced declines in lifespans, environmental deterioration that has affected health, and the efforts of the well-to-do to seal themselves off from the diseases of the less fortunate.
UnitedHealthcare is the nation’s largest health insurance company by market share. Stephen Maturen/Getty Images
But often left out is the fact that the Gilded Age confronted these issues; it was also, paradoxically, a period of reform. Beginning at the end of the 19th century, lifespans increased, childhood mortality fell, epidemic diseases declined, and public health produced remarkable results.
Now, that trajectory has reversed. Death and disease are at the heart of the murder of Brian Thompson, who was on his way to meet with investors hoping to profit from a company whose calculated decisions sentenced some people to suffer for the gain of others.
Useful questions might be: How did the Gilded Age escape its crises? And why did solutions that seemed to gradually improve health and well-being for most people over generations cease to work? How did UnitedHealthcare, the people who profit from it and those eager to invest in it come to be?
STM Daily News is a vibrant news blog dedicated to sharing the brighter side of human experiences. Emphasizing positive, uplifting stories, the site focuses on delivering inspiring, informative, and well-researched content. With a commitment to accurate, fair, and responsible journalism, STM Daily News aims to foster a community of readers passionate about positive change and engaged in meaningful conversations. Join the movement and explore stories that celebrate the positive impacts shaping our world.
Currently, getting a yearly COVID-19 vaccine is recommended for everyone ages 6 months and older, regardless of their health risk.
In the video announcing the plan to remove the vaccine from the CDC’s recommended immunization schedule for healthy children and healthy pregnant women, Kennedy spoke alongside National Institutes of Health Director Jay Bhattacharya and FDA Commissioner Marty Makary. The trio cited a lack of evidence to support vaccinating healthy children. They did not explain the reason for the change to the vaccine schedule for pregnant people, who have previously been considered at high-risk for severe COVID-19.
Similarly, in the FDA announcement made a week prior, Makary and the agency’s head of vaccines, Vinay Prasad, said that public health trends now support limiting vaccines to people at high risk of serious illness instead of a universal COVID-19 vaccination strategy.
Was this a controversial decision or a clear consensus?
Many public health experts and professional health care associations have raised concerns about Kennedy’s latest announcement, saying it contradicts studies showing that COVID-19 vaccination benefits pregnant people and children. The American College of Obstetrics and Gynecology, considered the premier professional organization for that medical specialty, reinforced the importance of COVID-19 vaccination during pregnancy, especially to protect infants after birth. Likewise, the American Academy of Pediatrics pointed to the data on hospitalizations of children with COVID-19 during the 2024-to-2025 respiratory virus season as evidence for the importance of vaccination.
Kennedy’s announcement on children and pregnant women comes roughly a month ahead of a planned meeting of the Advisory Committee on Immunization Practices, a panel of vaccine experts that offers guidance to the CDC on vaccine policy. The meeting was set to review guidance for the 2025-to-2026 COVID-19 vaccines. It’s not typical for the CDC to alter its recommendations without input from the committee.
Robert F. Kennedy Jr. has removed COVID-19 vaccines from the vaccine schedule for healthy children and pregnant people.
FDA officials Makary and Prasad also strayed from past established vaccine regulatory processes in announcing the FDA’s new stance on recommendations for healthy people under age 65. Usually, the FDA broadly approves a vaccine based on whether it is safe and effective, and decisions on who should be eligible to receive it are left to the CDC, which bases its decision on the advisory committee’s research-based guidance.
The advisory committee was expected to recommend a risk-based approach for the COVID-19 vaccine, but it was also expected to recommend allowing low-risk people to get annual COVID-19 vaccines if they want to. The CDC’s and FDA’s new policies on the vaccine will likely make it difficult for healthy people to get the vaccine.
Will low-risk people be able to get a COVID-19 shot?
Not automatically. Kennedy’s announcement does not broadly address healthy adults, but under the new FDA framework, healthy adults who wish to receive the fall COVID-19 vaccine will likely face obstacles. Health care providers can administer vaccines “off-label”, but insurance coverage is widely based on FDA recommendations. The new, narrower FDA approval will likely reduce both access to COVID-19 vaccines for the general public and insurance coverage for COVID-19 vaccines.
Under the Affordable Care Act, Medicare, Medicaid and private insurance providers are required to fully cover the cost of any vaccine endorsed by the CDC. Kennedy’s announcement will likely limit insurance coverage for COVID-19 vaccination.
Overall, the move to focus on individual risks and benefits may overlook broader public health benefits. Communities with higher vaccination rates have fewer opportunities to spread the virus.
This is an updated version of an article originally published on May 22, 2025.Libby Richards, Professor of Nursing, Purdue University
This article is republished from The Conversation under a Creative Commons license. Read the original article.
The All-New 2026 Nissan LEAF Is Here — Sleek, Smart, and Ready to Lead
Nissan has officially lifted the curtain on the all-new 2026 LEAF, and it’s not just an update—it’s a total reinvention. The third-generation LEAF blends sleek, aerodynamic styling with SUV-like proportions, signaling a bold departure from the hatchback form that defined the nameplate for over a decade. This refreshed design marks a new chapter for one of the world’s most accessible and best-selling electric vehicles.
With nearly 700,000 global sales under its belt, the LEAF has long been a pioneer in the mass-market EV space. The 2026 model takes that foundation and builds upon it in every direction—design, technology, comfort, and capability. Whether you’re a loyal EV enthusiast or making the switch from a gas-powered car, Nissan’s newest electric offering is designed to meet you where you are and elevate your driving experience.
The all-new LEAF sports clean, sculpted body lines and a wide stance that echoes modern crossover aesthetics. Inside, the cabin is minimal yet inviting, focused on comfort, spaciousness, and wellbeing. A dimming panoramic roof with heat shielding adds a premium touch, while ambient lighting in 64 available colors helps set the perfect mood for any drive.
Performance Meets Practicality
Among the most impressive upgrades is a liquid-cooled lithium-ion battery offering up to 75 kWh of usable capacity—meaning more range, more freedom, and more confidence. Faster charging speeds and the inclusion of the North American Charging Standard (NACS) port with Plug & Charge capability further simplify EV ownership.
Nissan’s all-new 3-in-1 powertrain—a compact, integrated system combining motor, inverter, and reducer—delivers both efficiency and power in a sleek package. It’s an engineering advancement that supports the LEAF’s mission of providing reliable, affordable electric mobility for all.
Tech-Savvy and Feature-Rich
This isn’t just a car—it’s a rolling tech hub. The 2026 LEAF offers dual 14.3-inch displays, wireless Apple CarPlay® and Android Auto™, and Google built-in features like Google Maps. Drivers will enjoy innovative tools like the Invisible Hood View, Front Wide View, and the 3D Intelligent Around View® Monitor—making tight parking and complex driving environments far easier to navigate.
Audiophiles take note: the available Bose® Personal® Plus audio system ensures that your soundtrack is every bit as premium as your ride.
Advertisement
Built to Impress, Ready for the Road
With details like flush door handles, holographic 3D tail lamps, and available 19-inch wheels, the 2026 LEAF is clearly designed to turn heads. But its mission is practical at heart: making electric driving seamless for everyday users. From its improved range to thoughtful in-cabin tech, Nissan is aiming squarely at the mainstream with this launch.
Assembly for the U.S. and Canadian markets will take place at Nissan’s Tochigi plant in Japan, where the LEAF will be built alongside the Ariya SUV.
The 2026 Nissan LEAF arrives at U.S. dealerships this fall, with availability in other global markets to follow.
Want more 2026 Nissan LEAF details or a feature breakdown?
Welcome to the Consumer Corner section of STM Daily News, your ultimate destination for savvy shopping and informed decision-making! Dive into a treasure trove of insights and reviews covering everything from the hottest toys that spark joy in your little ones to the latest electronic gadgets that simplify your life. Explore our comprehensive guides on stylish home furnishings, discover smart tips for buying a home or enhancing your living space with creative improvement ideas, and get the lowdown on the best cars through our detailed auto reviews. Whether you’re making a major purchase or simply seeking inspiration, the Consumer Corner is here to empower you every step of the way—unlock the keys to becoming a smarter consumer today!
The once red-hot U.S. residential solar market is showing signs of cooling off—but don’t count it out just yet. A combination of rising interest rates, regulatory changes, and supply chain challenges have led to a notable dip in installations across the country. But while the short-term trend suggests a slowdown, industry experts remain optimistic about the long-term potential of rooftop solar.
📉 The Numbers Don’t Lie: Installations Are Down
According to the Solar Energy Industries Association (SEIA) and Wood Mackenzie, residential solar installations dropped by 13% year-over-year in Q1 2025, with 1,106 megawatts (MW) installed nationwide. That’s also a 4% decline from the previous quarter. This marks a continuation of the trend that began in 2024, which saw the residential sector contract in 22 states—including a five-year low in California [^1].
Analysts at BloombergNEF predict that total U.S. solar capacity will fall by 7% between 2025 and 2027, with a projected 1% annual decline through 2035 under current policy scenarios [^2].
🧾 What’s Behind the Drop?
1. Higher Interest Rates
The Federal Reserve’s continued efforts to tame inflation have made financing solar systems more expensive for homeowners. The result? Fewer consumers are willing to commit to the upfront investment, even with long-term savings in play [^3].
2. Policy Shifts in Key States
California, long considered the leader in solar adoption, rolled back its Net Energy Metering (NEM) 2.0 program in favor of NEM 3.0, which significantly reduces the value of solar exports back to the grid. Installations in the state fell sharply as a result [^1].
On the federal side, proposed cuts to the 30% Investment Tax Credit (ITC)—a major driver of residential adoption—have caused uncertainty in the market. According to Reuters, solar stocks plummeted following changes in a Senate tax bill that threatened to shrink or eliminate these credits [^4].
Advertisement
3. Tariffs and Supply Constraints
Tariffs on Chinese and other foreign-made solar panels have led to price increases and reduced availability. Simultaneously, battery storage components are experiencing shortages, further delaying installations and complicating project timelines [^5].
🌤 The Long-Term Picture: A Resilient Future
Despite the headwinds, many in the industry see this as a short-term correction rather than a lasting decline. SEIA projects a return to 9% annual residential growth from 2025 to 2030, particularly if financing conditions improve and federal incentives remain intact [^1].
Additionally, solar panel prices remain historically low, hovering around $2.50–$2.60 per watt installed. That affordability, coupled with increasing demand for home electrification and EV charging solutions, makes rooftop solar an attractive long-term investment [^1].
In a recent industry survey, 78% of solar installers said they expect to sell as much or more in 2025 than they did in 2024 [^3]. And while the market is down in states like California, others—including Texas, Florida, and Arizona—are continuing to grow.
✅ Final Takeaway
Yes, residential solar is currently in a downturn. But it’s more of a recalibration than a collapse. Regulatory turbulence and financial pressures are squeezing the market, but the fundamentals—affordability, environmental benefits, and technological advancement—remain strong.
The future of residential solar will depend heavily on stable policy support, affordable financing, and continued innovation. If those stars align, the industry could see another boom in the latter half of the decade.
Advertisement
📚 Sources
[^1]: SEIA/Wood Mackenzie. U.S. Solar Market Insight Q1 2025.
STM Daily News is a vibrant news blog dedicated to sharing the brighter side of human experiences. Emphasizing positive, uplifting stories, the site focuses on delivering inspiring, informative, and well-researched content. With a commitment to accurate, fair, and responsible journalism, STM Daily News aims to foster a community of readers passionate about positive change and engaged in meaningful conversations. Join the movement and explore stories that celebrate the positive impacts shaping our world.
Privacy & Cookies: This site uses cookies. By continuing to use this website, you agree to their use.
To find out more, including how to control cookies, see here:
Cookie Policy
